STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00369499
Recruitment Status : Terminated (Not enough patients/ ethical concerns)
First Posted : August 29, 2006
Last Update Posted : February 25, 2008
Information provided by:
St. Jude Medical

August 28, 2006
August 29, 2006
February 25, 2008
March 2007
Not Provided
Mean values of the number of monthly migraine periods, with or without aura.
Same as current
Complete list of historical versions of study NCT00369499 on Archive Site
  • Mean values of monthly migraine frequency with or without aura.
  • Quality of life using a Headache Impact Test Questionnaire.
Same as current
Not Provided
Not Provided
STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?
STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?
The primary objective of this Study is to compare the effect of transcatheter device closure of atrial shunting to a non-closure control group over a period from cessation of procedure related medication at 3 months until 9 months post randomization by determining the proportion of patients that experience a 50% or more reduction in the baseline monthly migraine attack frequency in each group.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Device: PFO Closure
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
June 2009
Not Provided

Inclusion Criteria:

  • Migraine history of at least 1 year.
  • Migraine patients experiencing at least 2 migraine attacks per month.
  • Migraine patients experiencing at least 1 migraine attack with aura per month.
  • Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials. At least one of the classes shall come from beta-blockers, anticonvulsants, calcium channel blockers and tricyclic antidepressants.
  • Aged 18 - 50 years and of legal age in the host country.
  • The patient or legal guardian has signed a study specific informed consent form agreeing to data collection and follow-up requirements.
  • The patient agrees to abstain from starting prophylactic migraine medication or agrees to maintain existing prophylactic migraine medication without changing dose or drug from entering the baseline period throughout the duration of the study until final assessments.
  • Documented right to left shunt that is suitable for device closure.

Exclusion Criteria:

  • Taking migraine preventative medication for conditions other than migraine.
  • History of 15 or more headache days per month.
  • 8 or more non-migraine headache days per month.
  • Overuse of acute headache medication (use on 10 or more days per month).
  • Patient has severe central nervous system disease such as seizure disorder, inflammatory disease of the central nervous system, or a previous stroke.
  • Previous surgical or device closure of a PFO or ASD.
  • Artificial heart valve.
  • Pacemaker or ICD implanted within past 3 months.
  • Anatomic variant that could affect successful deployment such as coronary sinus, pulmonary veins, Chiari network.
  • Uncontrolled bacteremias or dental or surgical procedure within past 30 days or planned within study period.
  • Allergy to contrast media, and/or to any component of the device to be used.
  • Contraindicated for any medication used during or after the procedure.
  • History of atrial fibrillation or atrial flutter (chronic or paroxysmal).
  • Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.
  • Patient is undergoing dialysis for renal failure.
  • Patient has NYHA class 3 or 4 cardiac failure.
  • Patient is pregnant, or intends to become pregnant during the trial period.
  • Patient requires anticoagulation therapy for a concomitant condition.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
St. Jude Medical
Not Provided
Principal Investigator: Michel Ferrari, Prof. Leiden University Medical Centre
Principal Investigator: Horst Sievert, Prof. CardioVascular Center Frankfurt, Sankt Katharinen
St. Jude Medical
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP